Limosilactobacillus Reuteri Dsm 17938
Also known as: Limosilactobacillus reuteri, L. reuteri DSM 17938, Lactobacillus reuteri DSM 17938, Limosilactobacillus reuteri DSM 17938
Overview
*Limosilactobacillus reuteri* DSM 17938 is a probiotic strain that was previously classified as *Lactobacillus reuteri*. It is naturally found in the human gut and in various environmental sources. This strain is recognized for its capacity to improve gut health and is particularly beneficial for preterm infants and adults suffering from irritable bowel syndrome (IBS). Its key characteristics include anti-inflammatory effects and enhanced gut barrier function. Research maturity is classified as moderate to high, based on several systematic reviews and meta-analyses that have been conducted to evaluate its efficacy and safety. Overall, the evidence base includes randomized controlled trials (RCTs) which indicate positive health outcomes associated with its use, although some studies may have limitations regarding sample size or methodological quality.
Benefits
Numerous evidence-based benefits of *Limosilactobacillus reuteri* DSM 17938 have been identified. It shows significant effectiveness in preterm infants by reducing the incidence of necrotizing enterocolitis (NEC) and late-onset sepsis (LOS), and it notably shortens the time to full feeding by about 2.7 days. For adults with IBS, this probiotic improves global symptoms and significantly alleviates abdominal pain, bloating, and flatulence, with moderate effect sizes. Benefits in IBS symptoms can manifest from week 6 of treatment and can last up to 14 weeks. Some studies also suggest it may reduce infantile colic symptoms, although results are mixed.
How it works
*Limosilactobacillus reuteri* DSM 17938 functions by enhancing gut barrier integrity, reducing gastrointestinal inflammation, and modulating the gut microbiota. It primarily interacts with the gastrointestinal system, promoting the expression of tight junction proteins that help maintain epithelial barrier function. This mechanism facilitates a balanced microbial environment and mitigates the adverse effects of inflammatory responses in the gut.
Side effects
Overall, *Limosilactobacillus reuteri* DSM 17938 is regarded as safe, with no significant adverse effects consistently reported in clinical trials. Commonly observed side effects (>5%) have not been documented, and uncommon side effects (1-5%) are not well-established. Rare side effects (<1%) have not been reported. There are no significant drug interactions noted with this probiotic; however, it is recommended that caution be exercised in immunocompromised individuals, although no specific contraindications have been identified. As with any supplement, consulting a healthcare provider prior to use is advisable to ensure safety, especially in vulnerable populations.
Dosage
The typical dosage range for *Limosilactobacillus reuteri* DSM 17938 has not been precisely determined; however, it is commonly used in clinical studies at doses ranging from 10^8 to 10^9 CFU per day. This dosage is generally well-tolerated, and while no maximum safe dose has been established, higher doses are perceived to be well-consumed. Continuous use is recommended to ensure sustained health benefits. It is available in various delivery forms, including capsules and powders, which survive gastric transit, although specific absorption rates are not well-documented.
FAQs
How should I store *Limosilactobacillus reuteri*?
Store according to manufacturer instructions to maintain the probiotic's viability.
Is *Limosilactobacillus reuteri* safe for everyone?
Generally safe, but consult a healthcare provider before use, especially if immunocompromised.
How often should I take it?
Continuous daily use is recommended for optimal benefits.
When can I expect to see results?
Improvements in gut health and IBS symptoms may be visible within several weeks.
Is it a cure for gastrointestinal issues?
It is not a cure-all; benefits can vary based on individual conditions.
Research Sources
- https://pubmed.ncbi.nlm.nih.gov/37742098/ – This systematic review and meta-analysis assessed the effectiveness of *Limosilactobacillus reuteri* DSM 17938 in reducing NEC and LOS in preterm infants, highlighting its role in shortening time to full feeds. The evidence was rated as having very low certainty due to heterogeneity of studies.
- https://research-repository.uwa.edu.au/en/publications/limosilactobacillus-reuteri-dsm-17938-as-a-probiotic-in-preterm-i – The research focuses on the efficacy of *Limosilactobacillus reuteri* DSM 17938 as a probiotic for preterm infants, revealing significant improvements in gastrointestinal health outcomes but noting limitations in sample sizes and research design.
- https://www.frontiersin.org/journals/gastroenterology/articles/10.3389/fgstr.2023.1296048/full – This article discusses the benefits of *Limosilactobacillus reuteri* DSM 17938, emphasizing its ability to alleviate IBS symptoms as reported in a randomized controlled trial involving adults.
- https://pubmed.ncbi.nlm.nih.gov/29390535/ – A study examining the effects of *Limosilactobacillus reuteri* on IBS patients showed significant symptom improvements, although it had a smaller sample size and limited geographical diversity.
- https://www.bioscmed.com/index.php/bsm/article/download/457/629 – This systemic review evaluated the impact of *Limosilactobacillus reuteri* DSM 17938 on infant colic symptoms, presenting mixed results and identifying quality limitations across included studies.